Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation

Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation

2025.06.06
The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3( local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts.
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC

Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC

2025.05.28
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed  antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of just 8.5%—setting new records among global studies in this space.
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang

Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang

2025.05.19
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
ADC Research Led by Sun Yat-sen University Cancer Center May Influence Future Treatment Guidelines

ADC Research Led by Sun Yat-sen University Cancer Center May Influence Future Treatment Guidelines

2025.05.19
With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.